PDIA6 modulates apoptosis and autophagy of non-small cell lung cancer cells via the MAP4K1/JNK signaling pathway

Yuxin Bai¹,¹, Xuefeng Liu¹,¹, Xiaoyu Qi¹, Xuan Liu¹, Fang Peng¹, Huimin Li¹, Hailu Fu¹, Shimei Pei¹, Liying Chen¹, Xinming Chi¹, Liyuan Zhang¹, Xingbing Zhu¹, Yang Song¹, Yang Wang¹, Songshu Meng¹, Tao Jiang²,⁎⁎, Shujuan Shao²,⁎

¹ Key Laboratory of Proteomics, Dalian Medical University, Dalian 116044, China
² Department of Andrology, The First Hospital Affiliated of Dalian Medical University, Dalian 116011, China
³ Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China

Abstract

Background: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a poor prognosis. We previously found that protein disulfide isomerase family 6 (PDIA6) is upregulated in lung squamous cell carcinoma (LSCC). This study aimed to elucidate the clinical relevance, biological functions, and molecular mechanisms of PDIA6 in NSCLC.

Methods: The expression of PDIA6 in NSCLC was assessed using the TCGA database, western blotting, and immunohistochemistry. Correlations of PDIA6 expression with clinicopathological and survival features were evaluated. The functions of PDIA6 in regulating NSCLC cell growth, apoptosis, and autophagy were investigated using gain-and loss-of-function strategies in vitro or in vivo. The underlying molecular mechanisms of PDIA6 function were examined by human phospho-kinase array and co-immunoprecipitation.

Findings: PDIA6 expression was upregulated in NSCLC compared with adjacent normal tissues, and the higher PDIA6 expression was correlated with poor prognosis. PDIA6 knockdown decreased NSCLC cell proliferation and increased cisplatin-induced intrinsic apoptosis, while PDIA6 overexpression had the opposite effects. In addition, PDIA6 regulated cisplatin-induced autophagy, and this contributed to PDIA6-mediated apoptosis in NSCLC cells. Mechanistically, PDIA6 reduced the phosphorylation levels of JNK and c-Jun. Moreover, PDIA6 interacted with MAP4K1 and inhibited its phosphorylation, ultimately inhibiting the JNK/c-Jun signaling pathway.

Interpretation: PDIA6 is overexpressed in NSCLC and inhibits cisplatin-induced NSCLC cell apoptosis and autophagy via the MAP4K1/JNK/c-Jun signaling pathway, suggesting that PDIA6 may serve as a biomarker and therapeutic target for NSCLC patients.

Keywords: PDIA6, Apoptosis, Autophagy, MAP4K1, NSCLC

1. Introduction

Lung cancer is one of the most common forms of cancer, affecting both men and women worldwide [1]. Histologically, it can be divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Approximately 85% of lung cancer cases are diagnosed as NSCLC, and these can be further subdivided into two main subtypes: adenocarcinoma and squamous cell carcinoma [2]. Despite numerous advancements in early detection and treatment strategies over the past few decades, the five-year survival rate remains ~20% [1]. Thus, additional studies on the pathogenesis and molecular mechanisms of NSCLC will be vital to identify novel biomarkers for early detection and prediction of treatment responses and prognosis, as well as to uncover novel therapeutic targets.

Apoptosis or programmed cell death is often induced by chemotherapy agents and plays a critical role in clinical treatment of human cancers, which is regulated by many apoptosis-related genes and signaling pathways [3,4]. In addition, autophagy, a cell
Research in context

Evidence before this study

Previous reports have implicated PDIA6 in tumorigenesis. Our previous proteomic study also showed that PDIA6 is highly expressed in LSCC. However, the functions and molecular mechanisms of PDIA6 regarding apoptosis and autophagy have not been thoroughly assessed, especially in NSCLC.

The value of this study

This study aimed to elucidate the clinical relevance, biological functions, and molecular mechanisms of PDIA6 in NSCLC. We found that PDIA6 expression was elevated in NSCLC, and associated with a poor prognosis of NSCLC patients. Moreover, PDIA6 suppressed cisplatin-induced NSCLC cell apoptosis and autophagy through interacting with MAP4K1 to inhibit the JNK/c-Jun signaling pathway.

Implications of all the available evidence

These results indicate that PDIA6 has an oncogenic role and may be a potential biomarker and therapeutic target in NSCLC.

Mechanism by which cellular components are subjected to orderly degradation and recycling, has recently been suggested as a therapeutic target in cancer treatment and may be either cytotoxic [5–7] or cytotoxic during chemotherapy [8–10]. Interestingly, apoptosis and autophagy are closely linked and may both positively and negatively regulate each other [11]. For example, autophagy may regulate apoptosis via Atg5 and Atg12 which are important in apoptosis in response to diverse stress signals [12,13]. Other recent studies have revealed that apoptotic proteins, such as caspase-8 and caspase-9, are involved in the regulation of autophagy by targeting autophagy proteins [14,15].

In our previous study, we identified differentially expressed proteins between LSCC and adjacent normal tissues using two-dimensional gel electrophoresis (2D-DIGE) followed by mass spectrometry (MS) analysis [16]. Among these proteins, we focused on protein disulfide isomerase family 6 (PDIA6) for further analysis. PDIA6 is a member of the protein disulfide isomerase (PDI) family, which is mainly localized to the endoplasmic reticulum (ER) and functions as an oxidoreductase to catalyze disulfide bond formation and as a chaperone to assist in protein folding and inhibit aggregation of unfolded substrates [17,18]. Recent studies have reported that PDIA6 is upregulated in human cancers, such as liver cancer [19] and bladder cancer [20], and that knockdown of PDIA6 expression reduces bladder cancer cell proliferation and invasion [20]. Furthermore, PDIA6 mediates tumor cell resistance to cisplatin-induced apoptosis in lung adenocarcinoma [21]. However, the roles and molecular mechanisms of PDIA6 in NSCLC development and progression have yet to be elucidated.

In this study, we first evaluated PDIA6 expression in NSCLC samples and adjacent normal tissues, and examined the association of PDIA6 expression with clinicopathological and survival data from NSCLC patients. Next, we assessed the effects of PDIA6 knockdown and overexpression on NSCLC cell growth, apoptosis, and autophagy, as well as the underlying molecular events. We hypothesized that PDIA6 functions as an oncogene in NSCLC and may be valuable as a future therapeutic target or biomarker for NSCLC patients.

2. Material and methods

2.1. Clinical specimens

We obtained the tissue specimens from patients who received surgical resection of primary NSCLC in The First Affiliated Hospital of Dalian Medical University (Dalian, China). The use of the clinical specimens was approved by the Ethics Committee of Dalian Medical University, and all patients provided written informed consent. Furthermore, we also obtained primary human NSCLC tissue microarrays from Outdo Biotech (Shanghai, China), defined as cohort 1 (169 NSCLC and 164 corresponding adjacent normal samples) and cohort 2 (94 paired NSCLC and corresponding adjacent normal samples). Overall survival information and clinicopathological features of patients in cohort 1 were used for clinicopathological analysis.

2.2. Cell culture

Human lung cancer A549, NCI-H1299, NCI-H157, NCI-H460, NCI-H520, NCI-H446, and NCI-H358 cell lines, as well as two normal lung cell lines (HFL1 and HBE) and HEK293T were obtained from the American Type Culture Collection (ATCC) (Manassas, VA, USA). Lung adenocarcinoma Anip973 cell line was kindly provided by the Tumor Research Institute of Harbin Medical University. Lung adenocarcinoma SPC-A-1 cell line was purchased from the Chinese Academy of Sciences Committee Typical Culture Collection Cell Bank (Shanghai, China). These lung cell lines were grown in RPMI-1640 media (Gibco), while HEK293T cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM; Gibco), in a humidified incubator with 5% CO2 at 37 °C. All media were added with 10% fetal bovine serum (FBS; Gibco), 100 μg/ml of streptomycin and 100 U/ml of penicillin (Beyotime, Shanghai, China).

2.3. Western blotting

Total cellular protein from cell lines or lung cancer tissues was extracted using the radio-immunoprecipitation assay (RIPA) buffer (Beyotime, Shanghai, China) with protease inhibitors for 30 min at 4 °C, and then centrifuged at 12,000 rpm for 20 min at 4 °C to collect the supernatants. The concentrations of these protein samples were measured using the bicinchoninic acid (BCA) protein assay kit (Beyotime, Shanghai, China). Protein samples (30 μg for each lane) were separated in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and then transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA). After blocking with 5% non-fat milk, membranes were incubated with indicated primary antibodies at 4 °C overnight. On the next day, the membranes were incubated at room temperature for 1 h with corresponding anti-mouse or anti-rabbit IgG secondary antibody-conjugated with horseradish peroxidase (HRP). The protein bands were visualized using western bright ECL kit (Advansta, Menlo Park, CA, USA) followed by ChemiDoc™XRS+ system (Bio-Rad, USA). Antibodies used are listed in Table S1.

2.4. Immunohistochemistry (IHC)

The human NSCLC tissue microarrays and xenograft tumor tissue sections were deparaffinized in xylene and rehydrated through an ethanol series, followed by microwave in citrate buffer (pH 6.0) to repair antigens and treatment with 3% hydrogen peroxide to inhibit endogenous peroxidase activities. These tissue microarrays and sections were then blocked with 5% normal goat serum for 20 min at room temperature, and treated with antibody against PDIA6 (1:100; 18233–1-AP; RRID: AB_10805765), Ki-67 (1:800; 27309–2-AP; RRID: AB_2756525), MAP4K1 (1:100; bs-4134R; RRID: AB_11120767), or phospho-MAP4K1 (1:100; bs-5494R; RRID: AB_11093912) at 4 °C overnight. After washing, tissue microarrays and sections were incubated with...
Fig. 1. PDIA6 expression is elevated in NSCLC, and correlates with poor prognosis. (a) Expression of PDIA6 mRNA in lung cancer (T) and normal tissues (N) was analyzed by using TCGA database (p = 4.609e-52 by Wilcoxon test). (b, c) Western blotting analysis of the PDIA6 protein levels in 18 paired NSCLC tissues (T) and matched adjacent normal tissues (N), as well as in two normal lung cell lines (HBE and HFL1) and nine NSCLC cell lines (c). (d) Representative images (left) and IHC score (right) of PDIA6 expression in LSCC, LAD, and adjacent normal tissues in cohort 1 tissue microarrays, as determined by IHC staining. Original magnification, 40× (outside) or 400× (inset). Scale bar = 50 μm. Data is presented as the mean ± SD (**p < 0.01 and ***p < 0.001 by Student’s t-tests). (e) IHC score of PDIA6 expression in stage I (I), stage II (II), stage III (III), and normal tissues (N) of cohort 1. Data is displayed with the mean ± SD (**p < 0.01 and ***p < 0.001 by Student’s t-tests). (f, g) The Kaplan-Meier survival analysis of overall survival for NSCLC patients (f) or patients with stage I (g) in cohort 1 according to PDIA6 expression levels (p = 0.0043 in NSCLC, p = 0.0386 in stage I of NSCLC, log-rank test). (h, i) Univariate (h) and multivariate (i) Cox regression analyses of the correlation of overall survival with various clinical-pathological parameters as well as PDIA6 expression in cohort 1. 95% CIs and Hazard ratios are shown for each variable.
the pv-9000 kit (ZSGB-Bio, Beijing, China), visualized with 3,3-diaminobenzidine solution (ZSGB-Bio) treatment and counterstained with hematoxylin. The percentage (%) of positively stained cells was classified as 1 (0%–25%), 2 (26%–50%), 3 (51%–75%), or 4 (76%–100%), while the staining intensity was classified as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). We then multiplied these two scores to reach a staining index. The staining index ≥6 was defined as high PDIA6 expression, while the staining index ≥6 as high PDIA6 expression.

2.5. Stable cell line construction and transient knockdown

To establish stable cell lines with PDIA6 knockdown or overexpression, vectors containing short-hairpin RNA (shRNA) sequences against PDIA6 (plKO.1-PDIA6-shRNA1 and plKO.1-PDIA6-shRNA2) were generated by cloning the shRNAs into plKO.1 vector, while human pGMLV-P6A-PDIA6 and control vectors were obtained from Genomeditech (Shanghai, China). HEK293T cells were then cotransfected with PDIA6 shRNA vectors or pGMLV-P6A-PDIA6 vector together with packaging plasmids (psPAX2 and pMD2G), respectively. The viral supernatants were collected at 48–72 h after transfection. PDIA6 shRNA lentiviruses were used to infect NCI-H520 and Anip973 cells, while PDIA6 overexpression lentivirus infected A549 cells. After 24 h, cells were fed with 5 μg/ml puromycin-containing media to establish stable cell lines. The shRNA sequences are listed in Table S2.

To transiently knock down the expression of Atg5, JNK or MAP4K1, siRNA sequences targeting Atg5 [22], JNK, or MAP4K1, and negative control scramble sequence were designed and purchased from GenePharma (Shanghai, China). NCI-H520 and Anip973 cells were transiently transfected with these siRNA duplexes using Lipofectamine 2000 (Invitrogen) according to the kit instructions. The siRNA sequences are listed in Table S3.

2.6. Animal models

Male BALB/c nude mice (6 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology (Beijing, China). 2 × 10⁶ NCI-H520 control cells and PDIA6 knockdown cells were inoculated subcutaneously into the left and right armpits of mice (n = 7), respectively. The mice were then kept for 30 days. The tumor volume was monitored every 5 days with calipers, and was calculated with the following formula: volume = 0.5 × length × width². After the experiment was finished and xenograft tumors were resected, the mice were sacrificed and fixed. Cells were then randomly acquired using confocal microscope (Leica, Wetzlar, Germany). In GFP-LC3 assay, the average number of LC3 puncta of per cell was measured and photographed. Lastly, xenograft tumors were resected, fixed and trypsin-detached cells were plated into 6-well plates to grow overnight and further fixed in 1% osmium tetroxide (OsO₄) at 4 °C for 2 h. Then, cells were dehydrated in series of ethanol solutions from 50% to 100%, and subsequently embedded in Epon812 epoxyresin. Ultrathin sections (60–70 nm) were cut from the blocks by using a microtome, and stained with uranyl acetate and lead citrate. Finally, sections were reviewed under a TEM (JEM-2000EX, JEOL, Japan).

2.9. Acidine orange/ethidium bromide (AO/EB) double staining

Cell morphology of apoptosis was also visualized using the AO/EB dual staining (KeyGen Biotech Co., Ltd., Nanjing, China). NCI-H520/Anip973 control cells or PDIA6 knockdown cells were plated onto coverslips in 6-well plates to grow overnight. After pretreatment with or without 20 μM Z-VAD-FMK for 2 h, cells were incubated with 16 μM cisplatin for another 24 h. Then, cells were washed with 1 × PBS for three times, and infiltrated with the mixture of AO and EB solutions, followed by observation with a fluorescence microscope (Olympus, Tokyo, Japan).

2.10. Confocal microscope

GFP-tagged LC3 vector was purchased from Addgene. mRFP-GFP-tagged LC3 vector was kindly provided by Tomatsu Yoshimori (Osaka university, Osaka, Japan) [23]. NCI-H520/Anip973 control cells and PDIA6 knockdown cells were transiently transfected with GFP-LC3 vector or mRFP-GFP-LC3 vector using Lipofectamine 3000 (Invitrogen) according to the kit instructions. After 24 h of transfection, cells were incubated with 16 μM cisplatin for another 24 h. The images were then randomly acquired using confocal microscope (Leica, Wetzlar, Germany). In GFP-LC3 assay, the average number of LC3 puncta of per cell was calculated. For mRFP-GFP-LC3 system, the average number of yellow dots (autophagosomes) or red-only dots (autolysosomes) in the merged images of per cell was quantified.

Table 1

| Clinicopathological factor | Number of cases | PDIA6ᵃ | χ² | p       |
|---------------------------|-----------------|--------|----|---------|
|                            | High expression | Low expression |
| Age ≤60                   | 55              | 48     | 7  | 1.717   | 0.190  |
| ≥60                       | 114             | 90     | 24 |         |        |
| Gender Male               | 121             | 103    | 18 | 3.419   | 0.064  |
| Female                    | 48              | 35     | 13 |         |        |
| Tumor size <4 cm          | 61              | 47     | 14 | 1.353   | 0.245  |
| ≥4 cm                     | 108             | 91     | 17 |         |        |
| Pathological grading I    | 21              | 17     | 4  | 0.170   | 0.919  |
| II                        | 134             | 109    | 25 |         |        |
| III                       | 14              | 12     | 2  |         |        |
| Histological type LSCC    | 78              | 69     | 9  | 4.478   | 0.034ᵇ |
| LAD                       | 91              | 69     | 22 |         |        |
| Lymph node metastasis     | Positive        | 92     | 81 | 11      | 5.499  | 0.019ᵇ |
|                           | Negative        | 77     | 57 | 20      |        |        |
| TMM stage                 | I               | 54     | 37 | 17      | 10.78  | 0.005ᵇ |
|                           | II              | 69     | 58 | 11      |        |        |
|                           | III             | 46     | 43 | 3       |        |        |

ᵃ Data are shown as number of cases.
ᵇ Significant difference. The two tailed Pearson χ² test was employed to assess the correlation of PDIA6 expression with clinicopathological factors. p value <0.05 was recognized as statistically significant.
Fig. 2. Effects of Pdia6 on NSCLC cell growth in vitro and in vivo. (a, b) CCK-8 assay analysis of the impact of Pdia6 knockdown (a) or overexpression (b) on NSCLC cell growth. WT: wild type, shControl: shRNA control, shPdia6–1/2: shRNA-1/2 targeting Pdia6. Data is expressed as the mean ± SD (n = 3). (c, d) Colony formation assay showing the effects of Pdia6 knockdown (c) or overexpression (d) on NSCLC cell growth. Data is displayed with mean ± SD (n = 3, * * * p < 0.001 by Student’s t-tests). (e) The growth curves of xenograft tumors formed by NCI-H520 control cells (shControl) or Pdia6 knockdown cells (shPdia6–1) after injection of them in nude mice. Tumor volume was measured every 5 days. Data is expressed as the mean ± SD (n = 7, *** p < 0.001 by Student’s t-tests). (f) The tumors of two groups were isolated and compared. (g, h) The tumor volume (g) and weight (h) of two groups were measured and shown. Data is expressed as the mean ± SD (n = 7, *** p < 0.001 by Student’s t-tests). (i) Representative images of HE staining in tumors from two groups. Scale bar = 100 μm (left) or Scale bar = 10 μm (right). (j) IHC was used to measure the protein levels of Pdia6 and Ki-67 in tumors from two groups. Scale bar = 20 μm.
2.11. Human phospho-kinase array

The human phospho-kinase microarrays were obtained from R&D Systems (#ARY003; Minneapolis, MN, USA), and the assay were conducted according to manufacturer’s protocols. Briefly, cellular protein samples from NCI-H520 control cells and PDIA6 knockdown cells (600 μg protein of each) were incubated with the microarrays at 4 °C overnight. After mixture with biotin-labeled antibodies for 2 h, microarrays were incubated with HRP-streptavidin for 30 min at room temperature, and then detected using western bright ECL kit (Advansta, Menlo Park, CA, USA). Density was scanned with HLI mage software to quantify the data.

2.12. Luciferase reporter assay

AP-1 luciferase reporter (pAP-1–Luc), containing multiple AP-1 binding sites, was purchased from Genomeditech (Shanghai, China) to assess the activity of MAPK/JNK signaling pathway. A549 cells were co-transfected with pGMLV-P6A–PDIA6 (800 ng) or control vector (800 ng) together with pAP-1–Luc (200 ng) or pGM-Luc control reporter (200 ng), as well as pRL-TK Renilla reporter (8 ng) using Lipofectamine 3000 (Invitrogen) according to the kit instructions. After 48 h of transfection, total cellular protein was lysed, and the luciferase activities (Firefly and Renilla) were detected using the Dual-Luciferase Assay System (Promega, Madison, WI, USA).

2.13. Co-immunoprecipitation (Co-IP)

The co-immunoprecipitation assay was conducted using a co-immunoprecipitation kit (#26149; Pierce; Rockford, IL, USA) according to the kit’s protocols. In brief, 500 μg of NCI-H520 cell lysates for each sample was pre-cleared using a control agarose resin and then incubated with the column containing 5 μg antibody against PDIA6 (#18233–1-AP; RRID: AB_10805765) or IgG (#2729; RRID: AB_1031062) at 4 °C overnight. After washing to remove non-specific binding, the co-immunoprecipitated proteins were then eluted and analyzed by western blotting with the antibody for PDIA6 (#sc-374494; RRID: AB_10989559) or MAP4K1 (#bs-4134R; RRID: AB_11120767). The input was used as positive control, while IgG was used as negative control.

2.14. Mass spectrometry (MS)

The co-immunoprecipitated proteins were collected from the resin and separated through SDS-PAGE gels. After that, the gels were subject to silver staining with a kit from Beyotime (#P00175; Shanghai, China) according to the kit’s instructions. The differential bands specific to PDIA6 were in-gel digested with trypsin followed by the MS analysis using LTQ XL (Thermo Fisher Scientific, Waltham, MA, USA). The IgG was used as negative control.

2.15. Statistical analysis

The data were statistically analyzed by using either SPSS 21.0 or GraphPad Prism 5.0 software. All quantitative results were presented as mean ± SD. Statistical differences were analyzed with two-tailed Student’s t-test or one-way ANOVA. The association between PDIA6 expression and various clinicopathological features was evaluated using the χ2 test. The association of PDIA6 expression with overall survival was plotted by using the Kaplan-Meier curves, and the log-rank test was used to compare the significant differences. The univariate and multivariate analyses were performed by using the Cox proportional hazard model. P value < 0.05 was recognized to be statistically significant.

3. Results

3.1. PDIA6 is elevated in NSCLC tissues and cell lines

In our previous study, we identified proteins which were differentially expressed between LSCC and adjacent normal tissues using 2D-DIGE and MS analyses. PDIA6 was one of the upregulated proteins identified in LSCC tissues and was chosen for further analysis [16]. As shown in Fig. S1a, the mass signal for PDIA6 was a single peak. In addition, the mascot score was 62 (Fig. S1b) and the amino acid residues shown in red aligned with PDIA6 (Fig. S1c), collectively indicating that the MS results were reliable.

In the current study, we assessed PDIA6 expression levels in lung cancer by analyzing The Cancer Genome Atlas (TCGA) dataset and found that PDIA6 mRNA levels were significantly upregulated in lung cancer tissues (p = 4.609e-52 using the Wilcoxon test; Fig. 1a). Further analysis showed that PDIA6 protein levels were also higher in NSCLC tissues (n = 18) than in paired adjacent normal tissues and in nine NSCLC cell lines than in two normal lung cell lines, as measured by western blotting (Fig. 1b and c). In agreement with these results, immunohistochemistry (IHC) staining of two cohorts of NSCLC tissue microarrays showed strongly positive PDIA6 staining in both lung adenocarcinoma (LAD) and LSCC, but weakly positive or negative PDIA6 staining in adjacent normal tissues (Fig. 1d and Fig. S1d). Scoring of the IHC staining further confirmed that PDIA6 was highly expressed in both LAD and LSCC samples compared with adjacent lung tissues (Fig. 1d and Fig. S1d). Importantly, the PDIA6 IHC score was also elevated in stage I tumors versus normal tissues, and showed a gradual increase as the tumor stage progressed (Fig. 1e).

3.2. PDIA6 expression correlates with poor NSCLC prognosis

To elucidate the clinical relevance of PDIA6, we tested the potential association between PDIA6 expression and clinicopathological features in 169 NSCLC patients from cohort 1. As shown in Table 1, PDIA6 expression significantly correlated with TNM stage (p = 0.005), histological type (p = 0.034), and lymph node metastasis (p = 0.019), but not with gender, age, tumor size, or pathological grade. We then assessed the relationship between PDIA6 expression level and prognosis in NSCLC patients by Kaplan-Meier analysis. NSCLC patients with high PDIA6 expression levels had significantly reduced overall survival time than those with low PDIA6 expression levels (p = 0.0043, log-rank test, Fig. 1f). Interestingly, the association between high PDIA6 expression level and poor prognosis was only observed in LAD (p = 0.0002, log-rank test, Fig. S1e), and was not observed in LSCC (p = 0.1853, log-rank test, Fig. S1f). Consistent results were obtained when correlating PDIA6 mRNA expression with survival of LAD and LSCC patients using the Kaplan-Meier plotter database (www.kmplot.com) [24], and showed that higher expression of PDIA6 mRNA predicted poor overall survival in patients with LAD (p = 0.028, log-rank test, Fig. S1g). To evaluate the Utility of PDIA6 as a Biomarker of early NSCLC, Kaplan-

Fig. 3. PDIA6 inhibits cisplatin-induced apoptosis through the intrinsic apoptosis pathway in NSCLC cells. (a, b) Apoptotic rate was measured using annexin V/PI double staining in PDIA6 knockdown (a) or overexpression (b) cells treated with 16 μM (NCI-H520 and Anip973) or 13 μM (A549) cisplatin for 24 h, respectively. Data is expressed as the mean ± SD (n = 3, **p < 0.05, *p = 0.01 and "p = 0.001 by Student’s t-tests). (c) TEM analysis of cell ultrastructural characteristics in NCI-H520/Anip973 control cells or PDIA6 knockdown cells treated with 16 μM cisplatin for 24 h. Chromatin condensation and nuclear fragmentation are indicated by arrows. Scale bar = 2 μm. (d, e) Western blotting analysis of apoptosis-related protein levels in cells as in (a) and (b). (f) NCI-H520/Anip973 control cells or PDIA6 knockdown cells, pretreated with or without 20 μM Z-VAD-FMK, were incubated with 16 μM cisplatin for 24 h. Cells were then stained with ethidium bromide and acridine orange followed observation under a fluorescence microscope. Scale bar = 50 μm. (g) Western blotting analysis of cleaved caspase-3 levels in cells as in (f).
Meier analysis was performed on the NSCLC patients with stage I in cohort 1. This analysis revealed that high PDIA6 expression markedly correlated with shorter overall survival of stage I patients (p = 0.0386, log-rank test, Fig. 1g).

Next, we assessed the prognostic value of PDIA6 by univariate and multivariate Cox regression analyses in 169 NSCLC patients from cohort 1. Univariate Cox regression analysis revealed that PDIA6 expression, as well as TNM stage, pathological grade, lymph node metastasis, and histological type, were all significant predictors of overall survival in NSCLC patients (p = 0.005, 0.000, 0.044, 0.000, 0.000, respectively, Fig. 1h; Table S4). Importantly, PDIA6 expression was also an independent predictor of overall survival in NSCLC patients as shown by multivariant analysis [hazard ratio (HR) = 2.197, 95% confidence interval (CI) = 1.214–3.975, p = 0.009, Fig. 1i; Table S4].

3.3. PDIA6 promotes NSCLC cell proliferation

In order to investigate the role of PDIA6 in NSCLC cell malignant phenotypes, we used a lentiviruses-mediated strategy to establish cell lines stably expressing or knocking-down PDIA6. We confirmed that small hairpin RNAs (shRNAs) targeting PDIA6 noticeably reduced PDIA6 expression in NCI-H520 and Anip973 cells compared with the negative control shRNA (Fig. S2a), whereas A549 cells infected with a PDIA6 expressing lentivirus showed upregulated PDIA6 expression (Fig. S2b). After that, we assessed the effect of PDIA6 on NSCLC cell viability using the CCK-8 assay. The results showed that cell viability was decreased in NSCLC cells following PDIA6 knockdown, but increased in A549 cells overexpressing PDIA6, when compared to the corresponding control groups (Fig. 2a and b). Similar results were obtained in a colony formation assay (Fig. 2c and d). These findings indicate that PDIA6 functions as an oncogene to promote NSCLC cell proliferation.

3.4. PDIA6 knockdown inhibits NSCLC cell tumorigenesis in vivo

To further validate the oncocgenic activity of PDIA6 in vivo, nude mice were subcutaneously injected with NCI-H520 control cells and NCI-H520 cells with PDIA6 knockdown. As shown in Fig. 2e, PDIA6 knockdown significantly suppressed xenograft tumor growth as determined by growth kinetics. Xenograft tumors formed by cells with PDIA6 knockdown were much smaller than those of control tumors (Fig. 2f and g), The mean tumor weight was also decreased in the PDIA6 knockdown group (Fig. 2h). Furthermore, HE staining of the control xenografts showed that tumor cells were scattered in clusters or nests with enlarged and a typical nuclei containing prominent nucleoli, whereas PDIA6 knockdown xenografts lacked these obvious tumor cell phenotypes (Fig. 2i). Low PDIA6 expression in the PDIA6 knockdown group was confirmed by IHC (Fig. 2j). In addition, the expression of Ki-67, a proliferation marker, was downregulated in PDIA6 knockdown tumors as compared with the control (Fig. 2j). Taken together, our in vitro and in vivo experiments suggest that PDIA6 is critical for the growth of NSCLC cells.

3.5. PDIA6 inhibits cisplatin-induced apoptosis in NSCLC cells

We then evaluated whether PDIA6 is involved in modulating the apoptotic response in NSCLC cells. We measured apoptosis using annexin V/PI double staining, and our results showed that PDIA6 knockdown increased the apoptotic rate of NCI-H520 and Anip973 cells compared to control shRNA (Fig. S3a). Conversely, PDIA6 overexpression showed a trend towards decreased apoptosis in A549 cells, although this did not reach statistical significance (Fig. S3b). To further study the role of PDIA6 in this process, we treated these stable cell lines with cisplatin which is commonly used as a chemotherapeutic in treating numerous cancers, including NSCLC, and induces tumor cell apoptosis [25,26]. Knockdown of PDIA6 significantly increased cisplatin-induced apoptosis of NCI-H520 and Anip973 cells, while PDIA6 overexpression in A549 cells after cisplatin treatment decreased apoptosis (Fig. 3a and b). Consistently, DAPI staining also showed an increased apoptotic rate in PDIA6 knockdown NSCLC cells, and a decreased rate in PDIA6 overexpressing A549 cells, when compared with the corresponding control cells (Fig. S3c and d). Moreover, transmission electronic microscopic (TEM) data indicated that, upon cisplatin treatment, PDIA6 knockdown led to obvious ultrastructural changes in NCI-H520 and Anip973 cells, including disappearance of microvillus, chromatin condensation and nuclear fragmentation (Fig. 3c). Collectively, these data indicate that PDIA6 plays a role in suppressing cisplatin-induced apoptosis of NSCLC cells.

3.6. PDIA6 inhibits caspase-dependent apoptosis via intrinsic apoptosis pathway

In order to determine which apoptotic signaling pathway is primarily involved in the role of PDIA6 in cisplatin-induced apoptosis, we assessed the expression levels of apoptosis-related proteins by western blotting following cisplatin treatment. We found that knockdown of PDIA6 noticeably decreased Bcl-2 expression and induced the activation of caspase-9 and caspase-3 (Fig. 3d), two members of intrinsic apoptosis pathway [27]. In contrast, overexpression of PDIA6 in A549 cells had the opposite effect, leading to increased Bcl-2 expression and inhibited caspase activation (Fig. 3e). However, expression of caspase-8 and caspase-12, members of the extrinsic and ER stress-induced apoptotic pathways, respectively [28,29], did not noticeably change upon PDIA6 knockdown or overexpression (Fig. S3e and f), indicating that PDIA6 inhibits cisplatin-induced apoptosis through inhibition of the intrinsic apoptosis pathway rather than the extrinsic or ER stress-induced pathway.

To validate these findings, we treated PDIA6 knockdown NSCLC cells with Z-VAD-FMK, a pan-caspase inhibitor targeting caspase-3, and found that Z-VAD-FMK treatment noticeably suppressed PDIA6 knockdown-induced apoptosis as examined by ethidium bromide and acridine orange staining (Fig. 3f). Moreover, treatment with Z-VAD-FMK markedly decreased levels of cleaved caspase-3 in PDIA6 knockdown NSCLC cells (Fig. 3g), further implying that PDIA6 inhibits caspase-dependent apoptosis via the intrinsic apoptosis pathway.

3.7. PDIA6 inhibits cisplatin-induced autophagy in NSCLC cells

Our TEM data revealed that autophagy levels were also increased in PDIA6 knockdown NSCLC cells compared to control cells after cisplatin treatment (Fig. 4a). To confirm this phenomenon, more experiments were conducted to examine autophagy following cisplatin treatment. Firstly, NSCLC cells were stained with monodansylcadaverine (MDC), a bright vacuolar signal used to label...
autophagosomes. The results showed that PDIA6 knockdown NSCLC cells had increased staining intensity, but this intensity was decreased in PDIA6 overexpressing A549 cells, when compared to control cells (Fig. 5a and b). Autophagosomes were also assessed by GFP-LC3 dot formation after transfection of a GFP-LC3 plasmid. Consistently, the number of GFP-LC3 dots in PDIA6 knockdown NSCLC cells was higher than that of control cells (Fig. 4b), collectively indicating that PDIA6 inhibits the formation of cisplatin-induced autophagosomes in NSCLC cells.

To better understand the effect of PDIA6 on the autophagic process, we utilized the mRFP-GFP-LC3 double fluorescence system. This revealed that the numbers of both yellow dots (autophagosomes) and red-only dots (autolysosomes) increased in PDIA6 knockdown NSCLC cells, relative to control cells (Fig. 5e and Fig. S5d). Detection of autophagy-related protein expression using western blotting yielded similar results. PDIA6 knockdown resulted in upregulated levels of LC3II, Beclin1, and Atg5, but reduced levels of SQSTM1/p62 in NCI-H520 and Anip973 cells (Fig. 4c), whereas PDIA6 overexpression had the opposite effects on these proteins in A549 cells (Fig. 4d). Thus, these data support that PDIA6 exhibits an inhibitory effect on cisplatin-induced autophagy in NSCLC cells.

3.8. PDIA6-mediated autophagy contributes to apoptosis in NSCLC cells

To investigate whether PDIA6-mediated autophagy is related to cell death in NSCLC cells, we treated PDIA6 knockdown cells with an autophagy inhibitor, 3-MA. Similar to the pan-caspase inhibitor Z-VAD-FMK, 3-MA treatment alleviated PDIA6 knockdown-mediated inhibition of cell viability in NCI-H520 and Anip973 cells (Fig. S4c), suggesting that PDIA6 knockdown activates cytotoxic autophagy in NSCLC cells and autophagy is at least partially responsible for PDIA6 knockdown-mediated growth inhibition. In addition, annexin V/PI double staining showed that 3-MA-mediated autophagy inhibition also led to a decrease in PDIA6 knockdown-induced apoptosis in NCI-H520 and Anip973 cells (Fig. 4e). Consistently, the high levels of apoptosis-related proteins, including cleaved PARP and cleaved caspase-3, in PDIA6 knockdown NSCLC cells were downregulated following 3-MA treatment as measured by western blotting (Fig. 4f and Fig. S4d). In addition, downregulation of cleaved caspase-3 in PDIA6 knockdown NSCLC cells was also observed following siRNA-mediated Atg5 depletion (Fig. 4g and Fig. S4e). Our results indicate that inhibition of autophagy attenuates PDIA6 knockdown-induced apoptosis in NSCLC cells.

3.9. PDIA6 inhibits cisplatin-induced apoptosis and autophagy through JNK/c-Jun signaling pathway

Next, we conducted a human phospho-kinase array to identify potential signaling pathways involved in PDIA6-mediated inhibition of cisplatin-induced apoptosis and autophagy. We found that the levels of JNK phosphorylation at threonine 183 and tyrosine 185, and c-Jun phosphorylation levels, respectively. (b) Western blotting analysis of the impact of PDIA6 knockdown on the activity of JNK and c-Jun in NCI-H520 and Anip973 cells treated with 16 μM cisplatin for 24 h. Each phospho-protein is represented in duplicate. Red and blue boxes indicate noticeably altered differential bands specific for PDIA6 in NSCLC cells, we identified PDIA6-associated proteins by co-immunoprecipitation (Co-IP). As shown in Fig. 6a, we observed differential bands specific to PDIA6 in the silver stained SDS-PAGE gel as compared to IgG control. The presence of PDIA6 in the co-precipitated complexes was confirmed by western blotting of a parallel sample (Fig. 6a). Next, the differential protein bands were digested with trypsin and subjected to MS analysis. Among the candidate proteins, mitogen-activated protein kinase 1 (MAP4K1) was chosen for further analysis because it is an activator of JNK signaling pathway [30] and stably interacted with PDIA6 as validated by western blotting in both NCI-H520 and Anip973 cells (Fig. 6b). Furthermore, immunofluorescence staining of PDIA6 (red) and MAP4K1 (green) showed that the two proteins were co-localized in the cell cytoplasm upon cisplatin treatment (Fig. 6c).

3.10. PDIA6 interacts with MAP4K1 to inhibit JNK/c-Jun signaling pathway

To further explore the underlying molecular mechanisms of PDIA6 in NSCLC cells, we identified PDIA6-associated proteins by co-immunoprecipitation (Co-IP). As shown in Fig. 6a, we observed differential bands specific to PDIA6 in the silver stained SDS-PAGE gel as compared to IgG control. The presence of PDIA6 in the co-precipitated complexes was confirmed by western blotting of a parallel sample (Fig. 6a). Next, the differential protein bands were digested with trypsin and subjected to MS analysis. Among the candidate proteins, mitogen-activated protein kinase 1 (MAP4K1) was chosen for further analysis because it is an activator of JNK signaling pathway [30] and stably interacted with PDIA6 as validated by western blotting in both NCI-H520 and Anip973 cells (Fig. 6b). Furthermore, immunofluorescence staining of PDIA6 (red) and MAP4K1 (green) showed that the two proteins were co-localized in the cell cytoplasm upon cisplatin treatment (Fig. 6c).

Next, we investigated whether PDIA6 could affect MAP4K1 expression and found that, upon cisplatin treatment, MAP4K1 total mRNA or protein levels were not noticeably changed when PDIA6 was knockdown or overexpressed (Fig. 6d and e and Fig. S6a). However, PDIA6 knockdown increased the levels of phosphorylated MAP4K1 in NCI-

![Fig. 5. PDIA6 inhibits cisplatin-induced apoptosis and autophagy through JNK/c-Jun signaling pathway.](image-url)
a. Western blot analysis showing MAP4K1 and PDIA6 expression.
b. Immunoprecipitation (IP) analysis with NCI-H520 and Anip973 cell lines.
c. Confocal microscopy images showing PDIA6, MAP4K1, A549, and DAPI staining.
d. Western blot analysis of p-MAP4K1, MAP4K1, p-TAK1, TAK1, p-MKK7, MKK7, p-JNK, JNK, and PDIA6 in WT, shControl, shPDIA6-1, and shPDIA6-2.
e. Western blot analysis of p-MAP4K1, MAP4K1, p-TAK1, TAK1, p-MKK7, MKK7, p-JNK, JNK, and PDIA6 in WT, Vector, and PDIA6.
f. Immunohistochemistry images showing MAP4K1 and p-MAP4K1 expression.
g. Western blot analysis of p-MAP4K1, MAP4K1, p-JNK, JNK, p-c-Jun, JNK, and PDIA6 in shControl, shPDIA6-1, shPDIA6-2, and shMAP4K1.
h. Schematic diagram illustrating the role of PDIA6, MAP4K1, JNK, c-Jun, apoptosis, and autophagy in cell death induced by Cisplatin.

311–325
HS20 and Anip973 cells after cisplatin treatment (Fig. 6d). Consistent results were also observed in xenograft tumors, in which phospho-
MAP4K1, but not total MAP4K1, was upregulated in the PDIA6 knock-
down group compared to controls (Fig. 6f). In addition, the levels of phospho-TAK1 and phospho-MKK7, which are downstream of MAP4K1, were much higher in PDIA6 knockout NSCLC cells upon cis-
platin treatment, whereas total TAK1 and MKK7 protein levels were un-
changed (Fig. 6d). In agreement with these findings, PDIA6 overexpression had the opposite effect on MAP4K1, TAK1, and MKK7 phosphorylation (Fig. 6e). To confirm whether MAP4K1 is required for PDIA6 knockdown-induced JNK/c-Jun activation, we transfected PDIA6 knockdown NSCLC cells with MAP4K1 siRNA. Western blotting showed that depletion of MAP4K1 reduced JNK and c-Jun phosphorylation levels in PDIA6 knockdown cells upon cisplatin treatment (Fig. 6g). Collectively, these results indicate that MAP4K1 is involved in PDIA6-mediated inhibition of JNK/c-Jun signaling pathway.

4. Discussion

The PDI protein family consists of at least 21 members with a multidomain structure [31]. For example, PDI1 and PDA3 have four distinct domains, including two catalytically active a and a’ domains, as well as two catalytically inactive b and b’ domains, while PDIA6 lacks the b’ domain [32]. At present, mounting evidences support that PDI family members are highly expressed in several cancers with poor clinical outcome and increased metastasis, invasion and chemoresistance [33]. Soma Samanta et al., reported that PDI, PDIA6, PDIR, Erp57, Erp72, and AGR3 are overexpressed in ovarian cancer, and associated with poor survival in ovarian cancer with the exception of PDIA6 [34]. PDIA3 and PDIA6 expression is suggested to be aggressiveness marker in primary ductal breast cancer [35]. PDIA3 also func-
tions in inhibiting paclitaxel-induced apoptosis in ovarian cancer [36]. Additionally, recent studies found that Erp57 protects against apoptosis in autophagy-deficient cells [37]. Our previous study showed that PDIA6 is upregulated in LSCC tissues [16]. However, the molecular mecha-
nisms by which PDIA6 regulates tumor cell apoptosis and autophagy has not been thoroughly assessed, especially in lung cancer.

Apoptosis, a representative form of programmed cell death, can be induced by chemotherapeutic drugs via several pathways, such as the intrinsic and extrinsic pathways [38] or ER stress [39]. Caspases, a family of cysteine-dependent and aspartate directed proteases, play a vital role in apoptotic signaling pathways [40]. For example, caspases-8 and caspases-9 are responsible for activation of the extrinsic and intrinsic apoptosis pathways, respectively [27,28], while caspase-12 which res-
ides in the ER, is activated by ER stress and involved in ER-induced ap-
optosis [29]. In the present study, we found that PDIA6 suppressed cisplatin-induced NSCLC cell apoptosis by inhibiting caspase-9 and caspase-3 activation. This is in contrast to a previous study which showed that knockdown of PDIA6 expression sensitizes cisplatin-resistant NSCLC cells to cisplatin-induced cell death through modulating a non-canonical cell death pathway [21]. Although apoptosis is a very common form of programmed cell death, recent studies have highlighted the role of additional forms of cell death, such as autophagy-induced cell death [41]. In this process, autophagy could act in concert with apoptotic signaling and induce cell death [42]. Our study revealed that PDIA6 inhibited cisplatin-induced autophagy in NSCLC cells, which contributed to PDIA6-mediated NSCLC cell growth and apoptosis. Thus, autophagy may function as upstream of apoptosis in our study.

To elucidate the molecular mechanisms underlying PDIA6 regulated-apoptosis and autophagy induced by cisplatin, we used a human phospho-kinase array and observed that knockdown of PDIA6 in NSCLC cells induced JNK and c-Jun phosphorylation. Previous reports have shown that JNK (c-Jun NH 2-terminal kinase), a type of serine/threonine kinase belonging to the mitogen-activated protein ki-

MAP4K1, also referred to as human hematopoietic progenitor ki-
nase 1 (HPK1), is a member of the Ste20-related kinases family and is activated after tyrosine kinase induced phosphorylation [57]. Acti-
vated MAP4K1 will activate MAP3Ks, such as MKK1, MLK3, and
TAK1, which will then activate MKK4 or MKK7, ultimately leading to activation of the SAPK/JNK signaling pathway [30,58,59]. Here, we found that PDIA6 interacted with MAP4K1 and suppressed its phos-
phorylation after cisplatin treatment. Furthermore, MAP4K1 depletion resulted in decreased JNK and c-Jun activation in PDIA6 knockdown NSCLC cells after cisplatin treatment. Although PDIA6 wasn’t found to directly interact with JNK, PDIA6 may mediate repression of JNK ac-
tivation and c-Jun-dependent transcription in NSCLC cells via interac-
tion with MAP4K1. To the best of our knowledge, our current data is the first to show that PDIA6 interacts with MAP4K1 to repress JNK ac-
tivity after cisplatin treatment. Future studies will investigate how PDIA6 interaction with MAP4K1 changes MAP4K1 phosphorylation in NSCLC. In addition, studies have found that some PDI family pro-
teins are involved in cisplatin resistance, including PDIA6 [21,60]. Therefore, interference with the PDIA6-MAP4K1 binding may contrib-
ute to reverse of cisplatin resistance, which is worth further study in the future.

In summary, our current study demonstrates that PDIA6 is upregu-
lated in NSCLC, and correlates with poor prognosis for NSCLC patients. Moreover, PDIA6 functions as an oncogene that inhibits cisplatin-
induced NSCLC cell apoptosis and autophagy via interacting with MAP4K1 to suppress the JNK/c-Jun signaling pathway. Fig. 6h illustrates a model of PDIA6-regulated NSCLC cell apoptosis and autophagy. Thus, PDIA6 may serve as a potential biomarker for NSCLC diagnosis and pre-
diction of prognosis, and targeting PDIA6 may be a promising therapeu-
tic strategy for NSCLC patients.
Acknowledgements

This study was supported by the National Natural Science Foundation of China (No. 81470367, 81773122, and 21272032) and Institutions of higher learning of innovation team from Liaoning province (LT2014019). The funders did not have any role in study design, data collection, data analysis, interpretation, writing of the report.

Declaration of interests

There are no conflicts of interest among the authors.

Authors' contributions

Yuxin Bai designed, performed most of the experiments with assisted experimental contributions of Xuan Liu and Xiaoyu Qi. Yuxin Bai and Xuefeng Liu participated in data analyses and wrote the manuscript. Xuefeng Liu, Yang Wang and Songshu Meng provided conceptual advice and innovative idea. Fang Peng and Xinming Chi participated in immunohistochemical experiment and evaluation. Xinbing Zhu, Liying Chen and Hailiu Fu performed mouse experiments. Liyuan Zhang and Yang Song collected clinical specimens. Shimei Pei and Huimin Li provided bioinformatic analysis. Shujuan Shao and Tao Jiang supervised the work and reviewed this manuscript. All authors read and approved the final manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.03.045.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7–30.
[2] Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol 2015;16(21):e529–e40.
[3] Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009;16(7):966–977.
[4] Fulda S, Weigand MA, Bieser E, Rauch CT, Joz P, Blessing J et al. FADD-MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 2000;12(6):599–609.
[5] Hu MC, Qiu WR, Wang X, Meyer CF, Tan TH. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade. Genes Dev 1996;10(18):2251–64.
[6] Galligan J, Petersen DR. The human protein disulfide isomerase gene family. Hum Genomics 2012;6:6.
[7] Kozlov G, Maatantan P, Thomas DY, Gehring K. A structural overview of the PDI family of proteins. FEBS J 2010;277(19):3924–34.
[8] Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today 2014;19(3):222–30.
[9] Samanta S, Tamura S, Dubeau L, Mhawech-Fauceglia P, Miyagi Y, Kato H, et al. Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. Oncotarget 2017;8(7):41053–49.
[10] Ramos FS, Serino LT, Carvalho CM, Lima RS, Urban CA, Cavalli IJ, et al. PDA3 and PDA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genes, Chromosomes & Cancer 2015;54(4):360–61.
[11] Tufo G, Jones AW, Wang Z, Hamelin J, Tajeddine N, Esposti DD, et al. The protein disulfide isomerase P414A and P416A mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ 2014;21(5):685–95.
[12] Pan H, Zhang Y, Luo Z, Li P, Liu W, Wang C, et al. Autophagy mediates avian influenza H5N1 pseudotyped particle-induced lung inflammation through NF-kappaB and p38 MAPK signaling pathways. Am J Physiol Lung Cell Mol Physiol 2014;306(2):L183–95.
[13] Kimura S, Noda T, Yoshimori T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 2007;3(5):453–60.
[14] Menyhart O, Nagy A, Gyöfory B. Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci 2018;5(12):.
[15] Pignon JP, Tribout H, Scaglotti GV, Douillard JY, Shepherd FA, Stephens RJ et al. Lung cancer clinical trials: a pooled analysis by the LACE collaborative group. J Clin Oncol 2008;26(21):3552–9.
[16] Negroni L, Taouji S, Arma D, Pallares-Lupon N, Espositi DD, et al. The protein disulfide isomerase P414A and P416A mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ 2014;21(5):685–95.
[17] Chen and Hailiu Fu performed mouse experiments. Liyuan Zhang and Yang Song collected clinical specimens. Shimei Pei and Huimin Li provided bioinformatic analysis. Shujuan Shao and Tao Jiang supervised the work and reviewed this manuscript. All authors read and approved the final manuscript.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2019.03.045.
Li DD, Wang LL, Deng R, Tang J, Shen Y, Guo JF, et al. The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene 2009;28(6):886–98.

Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, et al. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer 2017;117(8):1139–53.

Lorin S, Borges A, Ribeiro Dos Santos L, Souquere S, Pierron G, Ryan KM, et al. c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagy and apoptosis in 2-methoxyestradiol-treated Ewing sarcoma cells. Cancer Res 2009;69(17):6924–31.

Gao GY, Ma J, Lu P, Jiang X, Chang C. Ophiopogonin B induces the autophagy and apoptosis of colon cancer cells by activating JNK/c-Jun signaling pathway. Biomed Pharmacother 2018;108:1208–15.

Yang J, Yao S, JNK-Bcl-2/Bcl-xl-Bax/Bak pathway mediates the crosstalk between matrine-induced autophagy and apoptosis via interplay with Beclin 1. Int J Mol Sci 2015;16(10):25744–58.

Zhang YX, Kong CZ, Wang HQ, Wang LH, Xu CL, Sun YH. Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis. Biochimie 2009;91(9):1173–9.

Wei Y, Pattingre S, Sinha S, Bassik M, Levine B. JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. Mol Cell 2008;30(6):678–88.